Compare PDFS & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDFS | PHAR |
|---|---|---|
| Founded | 1992 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2000 | 2020 |
| Metric | PDFS | PHAR |
|---|---|---|
| Price | $41.32 | $17.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $33.67 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 318.7K | 16.1K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.13 | $10.04 |
| Revenue Next Year | $18.92 | $2.51 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.63 | $8.04 |
| 52 Week High | $41.03 | $21.34 |
| Indicator | PDFS | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 73.34 | 62.36 |
| Support Level | $30.71 | $17.25 |
| Resistance Level | N/A | $18.30 |
| Average True Range (ATR) | 1.65 | 0.59 |
| MACD | 0.81 | 0.16 |
| Stochastic Oscillator | 91.99 | 84.95 |
PDF Solutions Inc provides products and services designed to empower organizations across the semiconductor and electronics ecosystem to connect, collect, manage, and analyze data about design, equipment, manufacturing, and test to improve the yield and quality of their products and operational efficiency. The Company's products, services, and solutions include proprietary software, physical intellectual property (IP) for integrated circuit (IC) designs, electrical measurement hardware tools, methodologies, and professional services.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.